[1]
|
Durrani, O.M., Meads, C.A. and Murray, P.I. (2004) Uveitis: A potentially blinding disease. Ophthalmologica, 21, 8223-8236.
|
[2]
|
Szekanecz, Z., Szanto, S., Szabo, Z., Vancsa, A., Szamosi, S., Bodnar, N., et al. (2010) Biologics-beyond the joints. Autoimmunity Reviews, 9, 820-824.
doi:10.1016/j.autrev.2010.07.011
|
[3]
|
Bell, G.M., Reynolds, G. and Isaacs, J.D. (2011) Biologic therapies in non-rheumatic diseases: Lessons for rheumatologists? Nature Reviews Rheumatology, 7, 507-516.
doi:10.1038/nrrheum.2011.106
|
[4]
|
Hyrich, K.L., Watson, K.D., Isenberg, D.A. and Symmons, D.P. (2008) The British Society for Rheumatology Biologics Register: 6 years on. Rheumatology (Oxford), 47, 1441-1443. doi:10.1093/rheumatology/ken242
|
[5]
|
Kahn, P., Weiss, M., Imundo, L.F. and Levy, D.M. (2006) Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology, 113, 860-864.
|
[6]
|
Emi Aikawa, N., de Carvalho, J.F., Artur Almeida Silva, C. and Bonfa, E. (2010) Immunogenicity of Anti-TNFalpha agents in autoimmune diseases. Clinical Reviews in Allergy & Immunology, 38, 82-89.
doi:10.1007/s12016-009-8140-3
|
[7]
|
Aaltonen, K.J., Virkki, L.M., Malmivaara, A., Konttinen, Y.T., Nordstrom, D.C. and Blom, M. (2012) Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One, 7, e30275.
doi:10.1371/journal.pone.0030275
|
[8]
|
Smith, J.R., Levinson, R.D., Holland, G.N., Jabs, D.A., Robinson, M.R., Whitcup, S.M., et al. (2001) Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis & Rheumatism, 45, 252-257. doi:10.1002/1529-0131(200106)45:3<252::AID-ART257>3.0.CO, 2-5
|
[9]
|
Sfikakis, P.P., Theodossiadis, P.G., Katsiari, C.G., Kaklamanis, P. and Markomichelakis, N.N. (2001) Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet, 358, 295-296.
doi:10.1016/S0140-6736(01)05497-6
|
[10]
|
Accorinti, M., Pirraglia, M.P., Paroli, M.P., Priori, R., Conti, F. and Pivetti-Pezzi, P. (2007) Infliximab treatment for ocular and extraocular manifestations of Behcet’s disease. Japanese Journal of Ophthalmology, 51, 191-196. doi:10.1007/s10384-006-0425-y
|
[11]
|
Tugal-Tutkun, I., Mudun, A., Urgancioglu, M., Kamali, S., Kasapoglu, E., Inanc, M., et al. (2005) Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease: An openlabel trial. Arthritis & Rheumatism, 52, 2478-2484.
doi:10.1002/art.21231
|
[12]
|
Russell, A.I., Lawson, W.A. and Haskard, D.O. (2001) Potential new therapeutic options in Behcet’s syndrome. BioDrugs, 15, 25-35.
doi:10.2165/00063030-200115010-00003
|
[13]
|
Pato, E., Munoz-Fernandez, S., Francisco, F., Abad, M.A., Maese, J., Ortiz, A., et al. (2011) Systematic review on the effectiveness of immunosuppressants and biological therapies in the treatment of autoimmune posterior uveitis. Seminars in Arthritis and Rheumatism, 40, 314-323.
doi:10.1016/j.semarthrit.2010.05.008
|
[14]
|
Evereklioglu, C. (2011) Ocular Behcet disease: current therapeutic approaches. Current Opinion in Ophthalmology, 22, 508-516. doi:10.1097/ICU.0b013e32834bbe91
|
[15]
|
Handa, T., Tsunekawa, H., Yoneda, M., Watanabe, D., Mukai, T., Yamamura, M., et al. (2011) Long-term remission of ocular and extraocular manifestations in Behcet’s disease using infliximab. Clinical and Experimental Rheumatology, 29, S58-63.
|
[16]
|
Keino, H., Watanabe, T., Taki, W. and Okada, A.A. (2011) Effect of infliximab on gene expression profiling in Behcet’s disease. Investigative Ophthalmology & Visual Science, 52, 7681-7686. doi:10.1167/iovs.11-7999
|
[17]
|
Keino, H., Okada, A.A., Watanabe, T. and Taki, W. (2011) Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy. British Journal of Ophthalmology, 95, 1245-1250.
doi:10.1136/bjo.2010.194464
|
[18]
|
Okada, A.A., Goto, H., Ohno, S. and Mochizuki, M. (2012) Multicenter study of infliximab for refractory uveoretinitis in Behcet disease. Archives of Ophthalmology, 130, 592-598.
doi:10.1001/archophthalmol.2011.2698
|
[19]
|
Cantini, F., Niccoli, L., Nannini, C., Kaloudi, O., Cassara, E., Susini, M., et al. (2012) Efficacy of infliximab in refractory Behcet’s disease-associated and idiopathic posterior segment uveitis: A prospective, follow-up study of 50 patients. Biologics, 6, 5-12.
|
[20]
|
Ito, T., Sonoda, K.H., Hijioka, K., Fujimoto, T. and Ishibashi, T. (2010) Acquired resistance to infliximab against uveitis due to Behcet’s disease after one year of administration. Japanese Journal of Ophthalmology, 54, 502-504. doi:10.1007/s10384-010-0859-0
|
[21]
|
Suhler, E.B., Smith, J.R., Wertheim, M.S., Lauer, A.K., Kurz, D.E., Pickard, T.D., et al. (2005) A prospective trial of infliximab therapy for refractory uveitis: Preliminary safety and efficacy outcomes. Archives of Ophthalmology, 123, 903-912. doi:10.1001/archopht.123.7.903
|
[22]
|
Benitah, N.R., Sobrin, L. and Papaliodis, G.N. (2011) The use of biologic agents in the treatment of ocular manifestations of Behcet’s disease. Seminars in Ophthalmology, 26, 295-303. doi:10.3109/08820538.2011.588665
|
[23]
|
Fries, W., Giofre, M.R., Catanoso, M. and Lo Gullo, R. (2002) Treatment of acute uveitis associated with Crohn’s disease and sacroileitis with infliximab. The American Journal of Gastroenterology, 97, 499-500.
doi:10.1111/j.1572-0241.2002.05514.x
|
[24]
|
Ally, M.R., Veerappan, G.R. and Koff, J.M. (2008) Treatment of recurrent Crohn’s uveitis with infliximab. The American Journal of Gastroenterology, 103, 2150-2151. doi:10.1111/j.1572-0241.2008.01982_12.x
|
[25]
|
Kruithof, E., Kestelyn, P., Elewaut, C., Elewaut, D., Van Den Bosch, F., Mielants, H., et al. (2002) Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis. Annals of the Rheumatic Diseases, 61, 470. doi:10.1136/ard.61.5.470
|
[26]
|
Baraliakos, X., van den Berg, R., Braun, J. and van der Heijde, D. (2012) Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology (Oxford), 51, 1378-1387. doi:10.1093/rheumatology/kes026
|
[27]
|
El Maghraoui, A. (2011) Extra-articular manifestations of ankylosing spondylitis: Prevalence, characteristics and therapeutic implications. European Journal of Internal Medicine, 22, 554-560. doi:10.1016/j.ejim.2011.06.006
|
[28]
|
Mangge, H., Heinzl, B., Grubbauer, H.M., El-Shabrawi, Y. and Schauenstein, K. (2003) Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatology International, 23, 258-261. doi:10.1007/s00296-003-0308-1
|
[29]
|
Sharma, S.M., Ramanan, A.V., Riley, P. and Dick, A.D. (2007) Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: Efficacy in joint and ocular disease. Annals of the Rheumatic Diseases, 66, 840-841. doi:10.1136/ard.2006.065441
|
[30]
|
Khalifa, Y.M., Bailony, M.R. and Acharya, N.R. (2010) Treatment of pediatric vogt-koyanagi-harada syndrome with infliximab. Ocular Immunology and Inflammation, 18, 218-222. doi:10.3109/09273941003739910
|
[31]
|
Sukumaran, S., Marzan, K., Shaham, B. and Reiff, A. (2012) High dose infliximab in the treatment of refractory uveitis: Does dose matter? ISRN Rheumatology, 2012, 765380.
|
[32]
|
Farvardin, M., Afarid, M. and Shahrzad, S. (2012) Longterm effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. Journal of Ocular Pharmacology and Therapeutics, 28, 628-631.
doi:10.1089/jop.2011.0199
|
[33]
|
Markomichelakis, N., Delicha, E., Masselos, S. and Sfikakis, P.P. (2012) Intravitreal infliximab for sight-threatening relapsing uveitis in behcet disease: A pilot study in 15 patients. American Journal of Ophthalmology, 154, 534-541. e1. doi:10.1016/j.ajo.2012.03.035
|
[34]
|
Rudwaleit, M., Rodevand, E., Holck, P., Vanhoof, J., Kron, M., Kary, S., et al. (2009) Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: Results of a prospective open-label study. Annals of the Rheumatic Diseases, 68, 696-701. doi:10.1136/ard.2008.092585
|
[35]
|
Mushtaq, B., Saeed, T., Situnayake, R.D. and Murray, P.I. (2007) Adalimumab for sight-threatening uveitis in Behcet’s disease. Eye (Lond), 21, 824-825.
doi:10.1038/sj.eye.6702352
|
[36]
|
Takase, K., Ohno, S., Ideguchi, H., Uchio, E., Takeno, M. and Ishigatsubo, Y. (2011) Successful switching to adalimumab in an infliximab-allergic patient with severe Behcet disease-related uveitis. Rheumatology International, 31, 243-245. doi:10.1007/s00296-009-1178-y
|
[37]
|
Kotaniemi, K., Saila, H. and Kautiainen, H. (2011) Longterm efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clinical Ophthalmology, 5, 1425-1429. doi:10.2147/OPTH.S23646
|
[38]
|
Erckens, R.J., Mostard, R.L., Wijnen, P.A., Schouten, J.S. and Drent, M. (2012) Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefe’s Archive for Clinical and Experimental Ophthalmology, 250, 713-720.
doi:10.1007/s00417-011-1844-0
|
[39]
|
Diaz-Llopis, M., Salom, D., Garcia-de-Vicuna, C., Cordero-Coma, M., Ortega, G., Ortego, N., et al. (2012) Treatment of refractory uveitis with adalimumab: A prospective multicenter study of 131 patients. Ophthalmology, 119, 1575-1581.
|
[40]
|
Leccese, P., Latanza, L., D’Angelo, S., Padula, A. and Olivieri, I. (2011) Efficacy of switching to adalimumab in a patient with refractory uveitis of Behcet’s disease to infliximab. Clinical and Experimental Rheumatology, 29, S93.
|
[41]
|
Bawazeer, A., Raffa, L.H. and Nizamuddin, S.H. (2010) Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocular Immunology and Inflammation, 18, 226-232. doi:10.3109/09273948.2010.483314
|
[42]
|
Dhingra, N., Morgan, J. and Dick, A.D. (2009) Switching biologic agents for uveitis. Eye, 23, 1868-1870.
doi:10.1038/eye.2009.203
|
[43]
|
Reiff, A., Takei, S., Sadeghi, S., Stout, A., Shaham, B., Bernstein, B., et al. (2001) Etanercept therapy in children with treatment-resistant uveitis. Arthritis & Rheumatism, 44, 1411-1415.
doi:10.1002/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO, 2-O
|
[44]
|
Quartier, P., Taupin, P., Bourdeaut, F., Lemelle, I., Pillet, P., Bost, M., et al. (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis & Rheumatism, 48, 1093-1101.
doi:10.1002/art.10885
|
[45]
|
Reddy, A.R. and Backhouse, O.C. (2003) Does etanercept induce uveitis? British Journal of Ophthalmology, 87, 925. doi:10.1136/bjo.87.7.925
|
[46]
|
Reiff, A. (2003) Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis & Rheumatism, 48, 2079-2080. doi:10.1002/art.11155
|
[47]
|
Schmeling, H. and Horneff, G. (2005) Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology, 44, 1008-1011.
doi:10.1093/rheumatology/keh658
|
[48]
|
Taban, M., Dupps, W.J., Mandell, B. and Perez, V.L. (2006) Etanercept (enbrel)-associated inflammatory eye disease: Case report and review of the literature. Ocular Immunology and Inflammation, 14, 145-150.
doi:10.1080/09273940600659393
|
[49]
|
Lim, L.L., Fraunfelder, F.W. and Rosenbaum, J.T. (2007) Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis & Rheumatism, 56, 3248-3252. doi:10.1002/art.22918
|
[50]
|
Gaujoux-Viala, C., Giampietro, C., Gaujoux, T., Ea, H.K., Prati, C., Orcel, P., et al. (2012) Scleritis: A paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. The Journal of Rheumatology, 39, 233-239.
doi:10.3899/jrheum.110865
|
[51]
|
Schafer, V.S. and Zwerina, J. (2012) Biologic treatment of large-vessel vasculitides. Current Opinion in Rheumatology, 24, 31-37. doi:10.1097/BOR.0b013e32834dc392
|
[52]
|
Muselier, A., Bielefeld, P., Bidot, S., Vinit, J., Besancenot, J.F. and Bron, A. (2011) Efficacy of tocilizumab in two patients with anti-TNF-alpha refractory uveitis. Ocular Immunology and Inflammation, 19, 382-383.
doi:10.3109/09273948.2011.606593
|
[53]
|
Shapiro, L.S., Farrell, J. and Haghighi, A.B. (2012) Tocilizumab treatment for neuro-Behcet’s disease, the first report. Clinical Neurology and Neurosurgery, 114, 297-298. doi:10.1016/j.clineuro.2011.10.024
|
[54]
|
Tappeiner, C., Heinz, C., Ganser, G. and Heiligenhaus, A. (2012) Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? The Journal of Rheumatology, 39, 1294-1295.
doi:10.3899/jrheum.120010
|
[55]
|
William, M., Faez, S., Papaliodis, G.N. and Lobo, A.M. (2012) Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. Journal of Ophthalmic Inflammation and Infection, 2, 231-233.
|
[56]
|
Planck, S.R., Woods, A., Clowers, J.S., Nicklin, M.J., Rosenbaum, J.T. and Rosenzweig, H.L. (2012) Impact of IL-1 signalling on experimental uveitis and arthritis. Annals of the Rheumatic Diseases, 71, 753-760.
doi:10.1136/annrheumdis-2011-200556
|
[57]
|
Teoh, S.C., Sharma, S., Hogan, A., Lee, R., Ramanan, A.V. and Dick, A.D. (2007) Tailoring biological treatment: Anakinra treatment of posterior uveitis associated with the CINCA syndrome. British Journal of Ophthalmology, 91, 263-264.
|
[58]
|
Gul, A., Tugal-Tutkun, I., Dinarello, C.A., Reznikov, L., Esen, B.A., Mirza, A., et al. (2012) Interleukin-1betaregulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet’s disease: An open-label pilot study. Annals of the Rheumatic Diseases, 71, 563-566.
doi:10.1136/annrheumdis-2011-155143
|
[59]
|
Smith, K.G., Jones, R.B., Burns, S.M. and Jayne, D.R. (2006) Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis & Rheumatism, 54, 2970-2982. doi:10.1002/art.22046
|
[60]
|
Meijer, J.M., Pijpe, J., Vissink, A., Kallenberg, C.G. and Bootsma, H. (2009) Treatment of primary Sjogren syndrome with rituximab: Extended follow-up, safety and efficacy of retreatment. Annals of the Rheumatic Diseases, 68, 284-285. doi:10.1136/ard.2008.092601
|
[61]
|
Smith, R.M., Jones, R.B., Guerry, M.J., Laurino, S., Catapano, F., Chaudhry, A., et al. (2012) Rituximab for remission maintenance in relapsing ANCA-associated vasculitis. Arthritis & Rheumatism, 64, 3760-3769.
doi:10.1002/art.34583
|
[62]
|
Nakken, B., Munthe, L.A., Konttinen, Y.T., Sandberg, A.K., Szekanecz, Z., Alex, P., et al. (2011) B-cells and their targeting in rheumatoid arthritis—Current concepts and future perspectives. Autoimmunity Reviews, 11, 28-34.
doi:10.1016/j.autrev.2011.06.010
|
[63]
|
Tappeiner, C., Heinz, C., Specker, C. and Heiligenhaus, A. (2007) Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Research, 39, 184-186. doi:10.1159/000103239
|
[64]
|
Davatchi, F., Shams, H., Rezaipoor, M., Sadeghi-Abdollahi, B., Shahram, F., Nadji, A., et al. (2010) Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study). International Journal of Rheumatic Diseases, 13, 246-252.
doi:10.1111/j.1756-185X.2010.01546.x
|
[65]
|
Heiligenhaus, A., Miserocchi, E., Heinz, C., Gerloni, V. and Kotaniemi, K. (2011) Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab). Rheumatology, 50, 1390-1394. doi:10.1093/rheumatology/ker107
|
[66]
|
Miserocchi, E. and Modorati, G. (2012) Rituximab for noninfectious uveitis. Developments in Ophthalmology, 51, 98-109. doi:10.1159/000336188
|
[67]
|
Zulian, F., Balzarin, M., Falcini, F., Martini, G., Alessio, M., Cimaz, R., et al. (2010) Abatacept for severe antitumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care & Research, 62, 821-825. doi:10.1002/acr.20115
|